Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: The St Jude Children's Research Hospital experience, 1962 to 1988

L. C. Bowman, M. L. Hancock, V. M. Santana, F. A. Hayes, L. Kun, D. M. Parham, W. L. Furman, B. N. Rao, A. A. Green, W. M. Crist

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

To gauge the impact of intensified therapy on the survival of infants (younger than 1 year, n = 129) and children (≥ 1 year of age, n = 275) with neuroblastoma, we analyzed the results of eight successive clinical trials comparing various combinations of antineoplastic drugs, surgery, and radiotherapy. Changes in treatment did not affect the survival of children with involved noncontiguous lymph nodes or distant metastatic disease until the combination of cisplatin and teniposide (CDDP/VM26) was added to a basic regimen of cyclophosphamide and doxorubicin (CTX/DOX). The resulting 4-year survival was 28% ± 5% (SE) compared with 7% ± 2% for previous treatments (P < .001 by the log-rank test). The 4-year survival of infants with metastatic disease was improved by administering CTX/DOX to all patients, reserving CDDP/VM26 for those whose disease was resistant to the former combination: 82% ± 6% versus 45% ± 8% in earlier studies; P < .001. In the subset of infants whose tumors had disseminated to bone or bone marrow at diagnosis, this therapeutic approach increased the probability of long-term survival from 48% ± 10% to 85% ± 9% (P = .01). The small group of children over 1 year of age with localized unresectable tumors also fared significantly better with the switch to CTX/DOX chemotherapy (4-year survival, 93% ± 7% v 42% ± 13%; P = .02). Multivariate analysis indicated that young age, limited-disease stage, nonadrenal primary site, and intensified treatment were independent predictors of a more favorable outcome. We conclude that substantial advances in the treatment of neuroblastoma have occurred over the past 25 years at this institution. The current overall 4-year survival probability of 57% ± 4% compares favorably with estimates for most other common solid tumors of childhood.

Original languageEnglish (US)
Pages (from-to)1599-1608
Number of pages10
JournalJournal of Clinical Oncology
Volume9
Issue number9
DOIs
StatePublished - Jan 1 1991

Fingerprint

Neuroblastoma
Survival
Research
Therapeutics
Antineoplastic Combined Chemotherapy Protocols
Teniposide
Neoplasms
Doxorubicin
Cyclophosphamide
Cisplatin
Radiotherapy
Multivariate Analysis
Lymph Nodes
Bone Marrow
Clinical Trials
Bone and Bones
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma : The St Jude Children's Research Hospital experience, 1962 to 1988. / Bowman, L. C.; Hancock, M. L.; Santana, V. M.; Hayes, F. A.; Kun, L.; Parham, D. M.; Furman, W. L.; Rao, B. N.; Green, A. A.; Crist, W. M.

In: Journal of Clinical Oncology, Vol. 9, No. 9, 01.01.1991, p. 1599-1608.

Research output: Contribution to journalArticle

Bowman, LC, Hancock, ML, Santana, VM, Hayes, FA, Kun, L, Parham, DM, Furman, WL, Rao, BN, Green, AA & Crist, WM 1991, 'Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: The St Jude Children's Research Hospital experience, 1962 to 1988', Journal of Clinical Oncology, vol. 9, no. 9, pp. 1599-1608. https://doi.org/10.1200/JCO.1991.9.9.1599
Bowman, L. C. ; Hancock, M. L. ; Santana, V. M. ; Hayes, F. A. ; Kun, L. ; Parham, D. M. ; Furman, W. L. ; Rao, B. N. ; Green, A. A. ; Crist, W. M. / Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma : The St Jude Children's Research Hospital experience, 1962 to 1988. In: Journal of Clinical Oncology. 1991 ; Vol. 9, No. 9. pp. 1599-1608.
@article{0315314a6e474b34935ba5980b5ce4c3,
title = "Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: The St Jude Children's Research Hospital experience, 1962 to 1988",
abstract = "To gauge the impact of intensified therapy on the survival of infants (younger than 1 year, n = 129) and children (≥ 1 year of age, n = 275) with neuroblastoma, we analyzed the results of eight successive clinical trials comparing various combinations of antineoplastic drugs, surgery, and radiotherapy. Changes in treatment did not affect the survival of children with involved noncontiguous lymph nodes or distant metastatic disease until the combination of cisplatin and teniposide (CDDP/VM26) was added to a basic regimen of cyclophosphamide and doxorubicin (CTX/DOX). The resulting 4-year survival was 28{\%} ± 5{\%} (SE) compared with 7{\%} ± 2{\%} for previous treatments (P < .001 by the log-rank test). The 4-year survival of infants with metastatic disease was improved by administering CTX/DOX to all patients, reserving CDDP/VM26 for those whose disease was resistant to the former combination: 82{\%} ± 6{\%} versus 45{\%} ± 8{\%} in earlier studies; P < .001. In the subset of infants whose tumors had disseminated to bone or bone marrow at diagnosis, this therapeutic approach increased the probability of long-term survival from 48{\%} ± 10{\%} to 85{\%} ± 9{\%} (P = .01). The small group of children over 1 year of age with localized unresectable tumors also fared significantly better with the switch to CTX/DOX chemotherapy (4-year survival, 93{\%} ± 7{\%} v 42{\%} ± 13{\%}; P = .02). Multivariate analysis indicated that young age, limited-disease stage, nonadrenal primary site, and intensified treatment were independent predictors of a more favorable outcome. We conclude that substantial advances in the treatment of neuroblastoma have occurred over the past 25 years at this institution. The current overall 4-year survival probability of 57{\%} ± 4{\%} compares favorably with estimates for most other common solid tumors of childhood.",
author = "Bowman, {L. C.} and Hancock, {M. L.} and Santana, {V. M.} and Hayes, {F. A.} and L. Kun and Parham, {D. M.} and Furman, {W. L.} and Rao, {B. N.} and Green, {A. A.} and Crist, {W. M.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1200/JCO.1991.9.9.1599",
language = "English (US)",
volume = "9",
pages = "1599--1608",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma

T2 - The St Jude Children's Research Hospital experience, 1962 to 1988

AU - Bowman, L. C.

AU - Hancock, M. L.

AU - Santana, V. M.

AU - Hayes, F. A.

AU - Kun, L.

AU - Parham, D. M.

AU - Furman, W. L.

AU - Rao, B. N.

AU - Green, A. A.

AU - Crist, W. M.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - To gauge the impact of intensified therapy on the survival of infants (younger than 1 year, n = 129) and children (≥ 1 year of age, n = 275) with neuroblastoma, we analyzed the results of eight successive clinical trials comparing various combinations of antineoplastic drugs, surgery, and radiotherapy. Changes in treatment did not affect the survival of children with involved noncontiguous lymph nodes or distant metastatic disease until the combination of cisplatin and teniposide (CDDP/VM26) was added to a basic regimen of cyclophosphamide and doxorubicin (CTX/DOX). The resulting 4-year survival was 28% ± 5% (SE) compared with 7% ± 2% for previous treatments (P < .001 by the log-rank test). The 4-year survival of infants with metastatic disease was improved by administering CTX/DOX to all patients, reserving CDDP/VM26 for those whose disease was resistant to the former combination: 82% ± 6% versus 45% ± 8% in earlier studies; P < .001. In the subset of infants whose tumors had disseminated to bone or bone marrow at diagnosis, this therapeutic approach increased the probability of long-term survival from 48% ± 10% to 85% ± 9% (P = .01). The small group of children over 1 year of age with localized unresectable tumors also fared significantly better with the switch to CTX/DOX chemotherapy (4-year survival, 93% ± 7% v 42% ± 13%; P = .02). Multivariate analysis indicated that young age, limited-disease stage, nonadrenal primary site, and intensified treatment were independent predictors of a more favorable outcome. We conclude that substantial advances in the treatment of neuroblastoma have occurred over the past 25 years at this institution. The current overall 4-year survival probability of 57% ± 4% compares favorably with estimates for most other common solid tumors of childhood.

AB - To gauge the impact of intensified therapy on the survival of infants (younger than 1 year, n = 129) and children (≥ 1 year of age, n = 275) with neuroblastoma, we analyzed the results of eight successive clinical trials comparing various combinations of antineoplastic drugs, surgery, and radiotherapy. Changes in treatment did not affect the survival of children with involved noncontiguous lymph nodes or distant metastatic disease until the combination of cisplatin and teniposide (CDDP/VM26) was added to a basic regimen of cyclophosphamide and doxorubicin (CTX/DOX). The resulting 4-year survival was 28% ± 5% (SE) compared with 7% ± 2% for previous treatments (P < .001 by the log-rank test). The 4-year survival of infants with metastatic disease was improved by administering CTX/DOX to all patients, reserving CDDP/VM26 for those whose disease was resistant to the former combination: 82% ± 6% versus 45% ± 8% in earlier studies; P < .001. In the subset of infants whose tumors had disseminated to bone or bone marrow at diagnosis, this therapeutic approach increased the probability of long-term survival from 48% ± 10% to 85% ± 9% (P = .01). The small group of children over 1 year of age with localized unresectable tumors also fared significantly better with the switch to CTX/DOX chemotherapy (4-year survival, 93% ± 7% v 42% ± 13%; P = .02). Multivariate analysis indicated that young age, limited-disease stage, nonadrenal primary site, and intensified treatment were independent predictors of a more favorable outcome. We conclude that substantial advances in the treatment of neuroblastoma have occurred over the past 25 years at this institution. The current overall 4-year survival probability of 57% ± 4% compares favorably with estimates for most other common solid tumors of childhood.

UR - http://www.scopus.com/inward/record.url?scp=0025769995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025769995&partnerID=8YFLogxK

U2 - 10.1200/JCO.1991.9.9.1599

DO - 10.1200/JCO.1991.9.9.1599

M3 - Article

C2 - 1831494

AN - SCOPUS:0025769995

VL - 9

SP - 1599

EP - 1608

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -